NASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $310.88 +1.50 (+0.48%) (As of 07/5/2024 08:52 PM ET) Add Compare Share Share Today's Range$308.57▼$313.4150-Day Range$273.94▼$319.3152-Week Range$218.44▼$329.72Volume1.27 million shsAverage Volume2.75 million shsMarket Capitalization$166.77 billionP/E Ratio44.41Dividend Yield2.90%Price Target$307.35 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amgen alerts: Email Address Amgen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.52 Rating ScoreUpside/Downside1.1% Downside$307.35 Price TargetShort InterestHealthy1.70% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-2.42Upright™ Environmental ScoreNews Sentiment1.45Based on 11 Articles This WeekInsider TradingSelling Shares$662,812 Sold Last QuarterProj. Earnings Growth5.55%From $19.47 to $20.55 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.59 out of 5 starsMedical Sector70th out of 879 stocksBiological Products, Except Diagnostic Industry8th out of 150 stocks 2.3 Analyst's Opinion Consensus RatingAmgen has received a consensus rating of Moderate Buy. The company's average rating score is 2.52, and is based on 11 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageAmgen has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.70% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amgen has recently increased by 0.77%, indicating that investor sentiment is decreasing. Previous Next 3.3 Dividend Strength Dividend YieldAmgen pays a meaningful dividend of 2.90%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Amgen is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 43.80% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmgen has received a 53.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Denosumab", "Etanercept", "Darbepoetin alfa", and "Apremilast" products. See details.Environmental SustainabilityThe Environmental Impact score for Amgen is -2.42. Previous Next 3.0 News and Social Media Coverage News SentimentAmgen has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Amgen this week, compared to 20 articles on an average week.Search InterestOnly 41 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.MarketBeat Follows27 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 59% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $662,812.00 in company stock.Percentage Held by InsidersOnly 0.69% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amgen are expected to grow by 5.55% in the coming year, from $19.47 to $20.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 44.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 44.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 156.71.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.81. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 26.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late. About Amgen Stock (NASDAQ:AMGN)Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More AMGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMGN Stock News HeadlinesJuly 2, 2024 | marketbeat.comBiotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex (AMGN)The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.June 17, 2024 | marketbeat.comModerna Stock Soars on Cutting-Edge Personalized Cancer Vaccines (AMGN)Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNAJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” July 6 at 8:31 AM | seekingalpha.comAmgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade)July 5 at 1:42 AM | seekingalpha.comAmgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong MomentumJuly 4, 2024 | investorplace.comThe 3 Best Healthcare Stocks to Buy in July 2024July 4, 2024 | fool.comForget Eli Lilly: 3 Biotech Stocks to Buy InsteadJune 29, 2024 | fool.com1 Dividend Growth Stock to Buy and Hold for 10 YearsJuly 8, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 28, 2024 | americanbankingnews.comArgus Increases Amgen (NASDAQ:AMGN) Price Target to $340.00June 28, 2024 | americanbankingnews.comAmgen Inc. to Post Q2 2025 Earnings of $5.05 Per Share, Zacks Research Forecasts (NASDAQ:AMGN)June 27, 2024 | 247wallst.comJefferies Red-Hot Summer Top Stock Picks Include 5 Blue Chip Dividend GiantsJune 27, 2024 | fool.comCan Amgen Stock Keep Trouncing the S&P 500?June 19, 2024 | stocknews.com3 Healthcare Stocks Benefiting From an Aging PopulationJune 17, 2024 | investorplace.com7 Breakthrough Biotech Stocks for a Shot of Portfolio AdrenalineJune 17, 2024 | seekingalpha.comAmgen: You Haven't Seen Anything YetJune 14, 2024 | seekingalpha.comFDA grants expanded approval for Amgen's Blincyto in ALLJune 14, 2024 | prnewswire.comFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASESee More Headlines Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Ex-Dividend for 6/7 Dividend5/16/2024Dividend Payable6/07/2024Today7/07/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CUSIP03116210 CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees26,700Year Founded1980Price Target and Rating Average Stock Price Target$307.35 High Stock Price Target$360.00 Low Stock Price Target$200.00 Potential Upside/Downside-1.1%Consensus RatingModerate Buy Rating Score (0-4)2.52 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$7.00 Trailing P/E Ratio44.41 Forward P/E Ratio15.97 P/E Growth2.81Net Income$6.72 billion Net Margins12.74% Pretax Margin14.71% Return on Equity156.21% Return on Assets10.82% Debt Debt-to-Equity Ratio11.96 Current Ratio1.42 Quick Ratio0.98 Sales & Book Value Annual Sales$28.19 billion Price / Sales5.92 Cash Flow$26.35 per share Price / Cash Flow11.80 Book Value$11.65 per share Price / Book26.68Miscellaneous Outstanding Shares536,430,000Free Float532,734,000Market Cap$166.77 billion OptionableOptionable Beta0.58 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Robert A. Bradway (Age 61)Chairman, CEO & President Comp: $6.73MMr. Peter H. Griffith (Age 65)Executive VP & CFO Comp: $3.07MMr. Esteban Santos (Age 56)Executive Vice President of Operations Comp: $3.01MDr. David M. Reese M.D. (Age 61)Executive VP & Chief Technology Officer Comp: $3.4MMr. Murdo Gordon (Age 57)Executive Vice President of Global Commercial Operations Comp: $3.24MMr. Matthew C. Busch (Age 50)Chief Accounting Officer & VP of Finance Mr. Mike ZahigianSenior VP & Chief Information OfficerDr. James E. Bradner M.D. (Age 52)Executive VP of Research and Development & Chief Scientific Officer Justin G. ClaeysVice President of Investor RelationsMr. Jonathan P. Graham (Age 63)Executive VP, General Counsel & Secretary Comp: $2.44MMore ExecutivesKey CompetitorsVertex PharmaceuticalsNASDAQ:VRTXRegeneron PharmaceuticalsNASDAQ:REGNGilead SciencesNASDAQ:GILDModernaNASDAQ:MRNASeagenNASDAQ:SGENView All CompetitorsInsiders & InstitutionsDNB Asset Management ASBought 41,809 shares on 7/5/2024Ownership: 0.028%Institutional & Family Asset Management LLCSold 340 shares on 7/5/2024Ownership: 0.003%HBW Advisory Services LLCBought 1,720 shares on 7/5/2024Ownership: 0.002%Thurston Springer Miller Herd & Titak Inc.Sold 22,251 shares on 7/5/2024Ownership: 0.001%Stokes Family Office LLCBought 136 shares on 7/5/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Amgen Stock? AMGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Amgen Inc.: Amgen has a diverse portfolio of products including Enbrel, Otezla, Prolia, and Repatha, which cater to various medical conditions, providing a stable revenue stream. Recent insider transactions indicate confidence in the company's performance, with senior vice president Nancy A. Grygiel purchasing shares at a price of $313.09, suggesting positive outlook. Amgen's consensus rating of "Moderate Buy" and an average price target of $305.65 indicate positive sentiment from analysts, potentially leading to stock price appreciation. Institutional investors, owning 76.50% of the stock, have been increasing their positions in Amgen, signaling strong institutional confidence in the company's future growth prospects. Amgen's stock price has shown resilience, with a 52-week high of $329.72, indicating potential for capital gains for investors. Cons Investors should be bearish about investing in Amgen Inc. for these reasons: Amgen's P/E ratio of 43.53 and a debt-to-equity ratio of 11.96 may indicate a relatively high valuation and leverage, potentially posing risks in case of economic downturns or industry challenges. The company's beta of 0.60 suggests lower volatility compared to the market, which may limit potential returns for investors seeking higher-risk investments. While Amgen has a strong product pipeline, competition in the biopharmaceutical industry is intense, leading to potential challenges in maintaining market share and pricing power. Amgen's 50-day and 200-day moving averages are close, indicating a potential consolidation phase or lack of clear trend in the stock price movement, which could deter short-term traders. Despite positive analyst ratings, any unforeseen regulatory issues, clinical trial failures, or patent expirations could negatively impact Amgen's stock performance in the future. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 23, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com. AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $288.02 on January 1st, 2024. Since then, AMGN shares have increased by 7.9% and is now trading at $310.88. View the best growth stocks for 2024 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Thursday, May, 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts' consensus estimates of $3.76 by $0.20. The company's revenue was up 22.0% compared to the same quarter last year. Read the conference call transcript. What is Robert A. Bradway's approval rating as Amgen's CEO? 1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend. Does Amgen have any subsidiaries? Amgen subsidiaries include these companies: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and others. Who are Amgen's major shareholders? Amgen's top institutional shareholders include DNB Asset Management AS (0.03%), Appleton Partners Inc. MA, Institutional & Family Asset Management LLC and Transcend Capital Advisors LLC. Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV) and Walt Disney (DIS). This page (NASDAQ:AMGN) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredI’m giving you the name of this investment for freeThis key unlocks a new pathway to wealth that has been kept hidden from you for decades. In my new documen...Porter & Company | SponsoredOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
